Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to diagnose Parkinson's earlier

NCT ID NCT06501469

Knowledge-focused Sponsor: Non-profit organization for scientific research in Parkinson's disease and related disorders Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to identify biomarkers—biological clues in the body—that can help distinguish between Parkinson's disease and similar conditions like progressive supranuclear palsy and multiple system atrophy. Researchers will follow people with early-stage parkinsonism and healthy volunteers for at least five years, collecting imaging scans, blood samples, and clinical data. The goal is to improve diagnosis and understanding of these disorders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to earlier and more accurate diagnosis of Parkinson's disease and related conditions, improving patient care and treatment development.
What could go wrong
This is an observational study, not a treatment trial, so it does not test any therapy. The findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* patients with unclassified Parkinsonism and disease duration \< 2 years * patients with suggestive, possible or probable progressive suprnanuclear palsy (PSP) according to established clinical criteria * patients with possible, probable or clinically confirmed multiple system atrophy (MSA) according to established clinical criteria * patients with Parkinson's disease (PD) according to established clinical criteria

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

IΙnclusion Criteria: * Written informed consent, including consent to monitoring * Patients with Parkinsonism and disease duration \< 2 years * Patients with Parkinsonism and disease duration \> 2 years * Healthy individuals without any neurological disease Exclusion Criteria: * Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide). * Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism). * Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm * Other serious diseases that indicate a life expectancy of \<5 years. * Active participation in other interventional clinical studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atypical parkinsonism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease parkinsonian disorder progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atypical parkinsonism Multiple system atrophy Parkinson disease Parkinsonism Progressive supranuclear palsy

Contacts and locations

Locations

  • HYGEIA Hospital, Parkinson's disease and Movement Disorders Department

    Athens, Athens, 15123, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.